Loading
Roivant Sciences Ltd. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest was filed 18 Sept 2025.
Roivant Sciences Ltd.: what insiders have been doing
Roivant Sciences Ltd., classified in the Health Care sector, is a listed company based in Hamilton, Bermuda, founded in 2014. Its insiders report their share dealings to SEC (Form 4). Over the twelve months to 18 October 2026, 127 filings were filed, from 18 insiders.
No insider bought on the market over the period, while 9 insiders filed 35 sales totalling €94.2M. The amount is not disclosed for 11 filings. Biggest ticket of the year: €14.9M, sold by Manchester Keith S and made public on 21 November 2025.
Filings reach the SEC (Form 4) feed a median of 2 days after the trade. Section 16 rules allow two business days to file each Form 4. Keep in mind that insiders sell for many reasons unrelated to the outlook, from tax bills to estate planning.
Across the 5,458 companies tracked on its exchange, the median is 22 filings; at 127 filings, this issuer sits above that mark. Our records for Roivant Sciences Ltd. go back to 2022, with 3 purchases and 86 sales on the open market in total. In its latest annual report filed with the SEC (10-K, fiscal year ended 31 March 2026), the company reported revenue of 8.3 m USD and net income of -299.8 m USD.
For comparison within the same sector, see the insider buying recorded at Anixa Biosciences Inc and Vivos Inc. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Insider Decl.
463
Thresholds
n/a
Buy Volume
€20M
3 ops. · all time
Sell Volume
€580M
86 ops. · all time
Who traded when
BuySaleKeith S. Manchester8 sales
Mayukh Sukhatme7 sales
Daniel Allen Gold6 sales
Epperly Melissa B,5 sales
Ramaswamy Vivek5 sales
Eric Venker3 sales
+3 other insiders
Since the insiders bought
- +122.9%Entry US$15.04 · Close 16 Oct 2026 US$33.53
- +63.7%Entry US$5.54 · Close at T+365 US$9.07
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analyst consensus: bullish or bearish?
Analysts rate Roivant Sciences Ltd. Strong Buy (bullish), based on 11 analysts. Average price target: US$48.27.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 15,928 of 24,148 companies
41.2
score / 100
Value27
Quality56
FCF yld-3.1%
Earn yld-1.2%
EV/EBITDA·
ROE-8.5%
Gross mgn84%
Net mgn·
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2026FY ended March 2026 · cache
US$33.53
Analyst consensus
11 analystsStrong buy
US$41.00Target US$48.27(+44%)US$55.00
Income statement
RevenueUS$8.3M
Gross profitUS$7M84% margin
EBITDA-US$1.3B-15520% margin
Net income-US$299.8M-3629.2% margin
Valuation
PER (forward)-19.5x
P/Book5.7x
Beta1.10
Balance sheet & cash
Market capUS$24.2B
Total debtUS$107.4M
Free Cash Flow-US$758.6M
Debt / Equity2%
Profitability & ownership
ROE-8.5%
ROA-16.5%
% insiders21.4%
% institutions78.4%
Last declaration on 5 October 2026
Declarations463 total
17,750 shares@ US$4.460.0003% mcap3.5% of flowCommon SharesSEC:0001807359-26-000018:0
16,850 shares@ US$36.080.0023% mcap27.1% of flowCommon SharesSEC:0001807359-26-000018:1
900 shares@ US$36.570.0001% mcap1.5% of flowCommon SharesSEC:0001807359-26-000018:2
46,879 shares@ US$36.570.0066% mcap1.5% of flowCommon SharesSEC:0001635088-26-000109:0
200,000 shares@ US$3.850.0029% mcap0.9% of flowCommon SharesSEC:0001635088-26-000108:0
200,000 shares@ US$36.620.028% mcap8.2% of flowCommon SharesSEC:0001635088-26-000108:1
76,171 shares@ US$36.570.011% mcap9.9% of flowCommon SharesSEC:0001140361-26-038475:0
40,309 shares@ US$36.570.0056% mcap10.0% of flowCommon SharesSEC:0001140361-26-038474:0
200,000 shares@ US$36.61780.028% mcap9.0% of flowCommonSEC144:0001965301-26-000150
2,129 shares@ US$39.770.0003% mcap3.8% of flowCommon SharesSEC:0001635088-26-000104:0
3,880 shares@ US$39.770.0006% mcap16.6% of flowCommon SharesSEC:0001140361-26-037363:0
5,054 shares0Common SharesSEC:0001807359-26-000016:0
5,054 shares0Common SharesSEC:0001349297-26-000010:0
5,054 shares0Common SharesSEC:0001635088-26-000102:0
5,054 shares0Common SharesSEC:0001140361-26-037158:0
5,054 shares0Common SharesSEC:0001209181-26-000007:0
600 shares@ US$40.380.0001% mcap1.6% of flowCommon SharesSEC:0001807359-26-000014:1
4,338 shares@ US$39.650.0007% mcap11.1% of flowCommon SharesSEC:0001807359-26-000014:0
4,712 shares@ US$39.680.0007% mcap10.0% of flowCommon SharesSEC:0001349297-26-000008:0
400 shares@ US$40.450.0001% mcap0.9% of flowCommon SharesSEC:0001349297-26-000008:1
22,688 shares@ US$41.020.0035% mcap60.4% of flowCommonSEC144:0001950047-26-009506
5,112 shares@ US$41.020.0008% mcap23.2% of flowCommonSEC144:0001950047-26-009495
2,179 shares@ US$40.940.0003% mcap5.7% of flowCommon SharesSEC:0001807359-26-000012:0
1,743 shares@ US$40.940.0003% mcap3.8% of flowCommon SharesSEC:0001349297-26-000006:0
25 of 463 declarations
About Roivant Sciences Ltd.
Roivant Sciences Ltd. is a biopharmaceutical company focused on developing innovative medicines to address unmet medical needs. It employs a technology-driven approach to accelerate the drug discovery and development process.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
